147 related articles for article (PubMed ID: 16001170)
1. Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells.
Michelutti A; Stocchi R; Candoni A; Tiribelli M; Calistri E; Russo D; Fanin R; Damiani D
Cancer Chemother Pharmacol; 2006 Apr; 57(4):517-24. PubMed ID: 16001170
[TBL] [Abstract][Full Text] [Related]
2. Amifostine does not inhibit the toxic effects of anthracycline derivates or mitoxantrone on MDR tumor cell lines.
Michieli M; Michelutti A; Damiani D; Ermacora A; Masolini P; Stocchi R; Russo D
Leuk Lymphoma; 2001 Aug; 42(4):721-9. PubMed ID: 11697502
[TBL] [Abstract][Full Text] [Related]
3. Enhancement of fotemustine (Muphoran) cytotoxicity by amifostine in malignant melanoma cell lines.
Merlin JL; Marchal S; Ramacci C; Berlion M; Poullain MG
Anticancer Drugs; 2002 Feb; 13(2):141-7. PubMed ID: 11901306
[TBL] [Abstract][Full Text] [Related]
4. Effects of WR-2721 (amifostine) and its metabolite WR-1065 on the antiproliferative activity of chemotherapeutic agents on neuroblastoma cells in vitro.
Fulda S; Oster W; Berthold F
Anticancer Drugs; 1997 Jan; 8(1):34-41. PubMed ID: 9147609
[TBL] [Abstract][Full Text] [Related]
5. Liposomal daunorubicin plasmatic and renal disposition in patients with acute leukemia.
Pea F; Russo D; Michieli M; Baraldo M; Ermacora A; Damiani D; Baccarani M; Furlanut M
Cancer Chemother Pharmacol; 2000; 46(4):279-86. PubMed ID: 11052625
[TBL] [Abstract][Full Text] [Related]
6. Liposomal encapsulation diminishes daunorubicin-induced generation of reactive oxygen species, depletion of ATP and necrotic cell death in human leukaemic cells.
Liu FT; Kelsey SM; Newland AC; Jia L
Br J Haematol; 2002 May; 117(2):333-42. PubMed ID: 11972515
[TBL] [Abstract][Full Text] [Related]
7. Amifostine protects primitive hematopoietic progenitors against chemotherapy cytotoxicity.
List AF; Heaton R; Glinsmann-Gibson B; Capizzi RL
Semin Oncol; 1996 Aug; 23(4 Suppl 8):58-63. PubMed ID: 8783669
[TBL] [Abstract][Full Text] [Related]
8. Liposome-encapsulated daunorubicin for PGP-related multidrug resistance.
Michieli M; Damiani D; Ermacora A; Masolini P; Michelutti A; Michelutti T; Russo D; Pea F; Baccarani M
Br J Haematol; 1999 Jul; 106(1):92-9. PubMed ID: 10444168
[TBL] [Abstract][Full Text] [Related]
9. Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia.
Russo D; Piccaluga PP; Michieli M; Michelutti T; Visani G; Gugliotta L; Bonini A; Pierri I; Gobbi M; Tiribelli M; Fanin R; Piccolrovazzi S; Baccarani M
Ann Hematol; 2002 Aug; 81(8):462-6. PubMed ID: 12224004
[TBL] [Abstract][Full Text] [Related]
10. In vitro cellular accumulation and cytotoxicity of liposomal and conventional formulations of daunorubicin and doxorubicin in resistant K562 cells.
Wang Y; Eksborg S; Lewensohn R; Lindberg A; Liliemark E
Anticancer Drugs; 1999 Nov; 10(10):921-8. PubMed ID: 10630360
[TBL] [Abstract][Full Text] [Related]
11. Interaction of amifostine and ionizing radiation on transcriptional patterns of apoptotic genes expressed in human microvascular endothelial cells (HMEC).
Khodarev NN; Kataoka Y; Murley JS; Weichselbaum RR; Grdina DJ
Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):553-63. PubMed ID: 15380592
[TBL] [Abstract][Full Text] [Related]
12. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine.
Capizzi RL
Semin Oncol; 1999 Apr; 26(2 Suppl 7):3-21. PubMed ID: 10348255
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of liposomal daunorubicin and cytarabine as reinduction chemotherapy in relapsed acute lymphoblastic leukaemia despite expression of multidrug resistance-related proteins.
Candoni A; Michelutti A; Simeone E; Damiani D; Baccarani M; Fanin R
Eur J Haematol; 2006 Oct; 77(4):293-9. PubMed ID: 16856922
[TBL] [Abstract][Full Text] [Related]
14. Liposomal daunorubicin: in vitro and in vivo efficacy in multiple myeloma.
Pratt G; Wiles ME; Rawstron AC; Davies FE; Fenton JA; Proffitt JA; Child JA; Smith GM; Morgan GJ
Hematol Oncol; 1998 Jun; 16(2):47-55. PubMed ID: 10065112
[TBL] [Abstract][Full Text] [Related]
15. In vitro sensitivity to the liposomal preparation, DaunoXome in CLL.
Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
Anticancer Res; 1999; 19(4B):3253-7. PubMed ID: 10652620
[TBL] [Abstract][Full Text] [Related]
16. Selective exclusion by the polyamine transporter as a mechanism for differential radioprotection of amifostine derivatives.
Quiñones HI; List AF; Gerner EW
Clin Cancer Res; 2002 May; 8(5):1295-300. PubMed ID: 12006551
[TBL] [Abstract][Full Text] [Related]
17. WR-1065, the active metabolite of amifostine, mitigates radiation-induced delayed genomic instability.
Dziegielewski J; Baulch JE; Goetz W; Coleman MC; Spitz DR; Murley JS; Grdina DJ; Morgan WF
Free Radic Biol Med; 2008 Dec; 45(12):1674-81. PubMed ID: 18845240
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of liposomal daunorubicin in relapsed and refractory acute myeloid leukemia.
Bieker R; Lerchenmüller C; Wehmeyer J; Serve HL; Mesters RM; Büchner T; Berdel WE
Oncol Rep; 2003; 10(4):915-20. PubMed ID: 12792745
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of liposomal anthracyclines in phase I/II clinical trials.
Alberts DS; Muggia FM; Carmichael J; Winer EP; Jahanzeb M; Venook AP; Skubitz KM; Rivera E; Sparano JA; DiBella NJ; Stewart SJ; Kavanagh JJ; Gabizon AA
Semin Oncol; 2004 Dec; 31(6 Suppl 13):53-90. PubMed ID: 15717738
[TBL] [Abstract][Full Text] [Related]
20. Differential activation of nuclear transcription factor kappaB, gene expression, and proteins by amifostine's free thiol in human microvascular endothelial and glioma cells.
Grdina DJ; Murley JS; Kataoka Y; Calvin DP
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):103-11. PubMed ID: 11917294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
